Acro Biomedical (ACBM) Net Margin (2017 - 2022)

Acro Biomedical's Net Margin history runs 6 years deep, the most recent figure standing at 1092.97% for Q4 2022.

• In Q4 2022, Net Margin fell 44925.0% year-over-year to 1092.97%; the TTM figure through Sep 2023 stood at 3534.45% (down 177358.0% YoY), while the FY2022 annual figure was 2410.24%, down 176770.0% from the prior year.
• Net Margin was 1092.97% for Q4 2022 at Acro Biomedical, up from 1316.18% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 11.79% in Q1 2020 to a low of 1316.18% in Q1 2022.
• Historically, Net Margin has averaged 299.03% across 5 years, with a median of 39.2% in 2019.
• The sharpest annual moves came in 2018 and 2022: Net Margin plunged 1109 bps in 2018, then tumbled 125639 bps in 2022.
• A 5-year view of Net Margin shows it stood at 5.54% in 2018, then plunged by 608 bps to 39.2% in 2019, then surged by 130 bps to 11.79% in 2020, then slumped by 5560 bps to 643.72% in 2021, then slumped by 70 bps to 1092.97% in 2022.
• The last three Net Margin figures came in at 1092.97% (Q4 2022), 1316.18% (Q1 2022), and 643.72% (Q4 2021), per Business Quant data.